Patient support


MS LifeLines® is an educational patient support service for people living with MS and their families, and is sponsored by EMD Serono, Inc.


MS LifeLines logo


Through MS LifeLines®, patients have access to individualized support and educational resources to help them make the most of their treatment with Rebif®. Financial support specialists can help patients understand insurance coverage and assistance programs, and MS-certified nurses are available to assist patients with treatment questions. Tell your patients to visit or call 1-877-447-3243 to learn more about MS LifeLines®.

Rebif® has formulary coverage across a range of plans, including private and government insurance.

Access and coverage

Your MS LifeLines® Case Manager can provide you with information about:

  • Local payer coverage
  • Support for patients in finding the most appropriate specialty pharmacy
  • Payer prior-authorization requirements, utilization management criteria, and appeals process
  • Education for office staff on MS LifeLines® and how to help patients enroll in this program
  • Information on MS LifeLines® financial support programs available for eligible patients

MS Lifelines® can help patients:

  • Navigate insurance access by working with specialty pharmacies preferred by patient in order to facilitate access for patient
  • Get information about financial assistance options
  • Learn about educational events sponsored by EMD Serono
  • Locate additional support resources such as advocacy groups

MS LifeLines® Nurse Support Specialists

From the first dose and throughout their relapsing MS journey with Rebif®, MS LifeLines® offers individualized support for your patients. Even if they have been living with MS for a long time, they can still benefit from connecting with an MS LifeLines® Nurse.


$0 co-pay for eligible patients icon

Patients may pay as little as $0 co-pay*

For eligible commercially insured patients who have been prescribed Rebif®, MS LifeLines® offers a copay assistance program that could reduce their out-of-pocket costs (including copays and deductibles) to as little as $0.

*Federal and state healthcare program beneficiaries (such as Medicare or Medicaid) are not eligible for copay assistance.


RX prescription icon

Free medication may be available for eligible patients

MS LifeLines® also offers other assistance programs, including free medication to eligible patients to help ensure appropriate patients have access to Rebif®.

Call MS LifeLines® Financial Support Specialists at 1-877-447-3243 to determine if your uninsured or underinsured patients are eligible for an MS LifeLines® financial assistance program. 


Important Safety Information

Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.

Rebif should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.

Severe liver injury, including some cases of hepatic failure requiring liver transplantation, has been reported rarely in patients taking Rebif. The potential for liver injury should be considered when used in combination with other products associated with liver injury. Monitor liver function tests and patients for signs and symptoms of hepatic injury. Consider discontinuing Rebif if hepatic injury occurs.

Anaphylaxis and other allergic reactions (some severe) have been reported as a rare complication of Rebif. Discontinue Rebif if anaphylaxis occurs.

In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, discontinue Rebif until skin lesions are healed.

Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.

Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated.

Caution should be exercised when administering Rebif to patients with pre-existing seizure disorders. Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports.

The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.

Epidemiological data do not suggest a clear relationship between interferon beta use and major congenital malformations, but interferon beta may cause fetal harm based on animal studies. Data from a large human population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with interferon beta products during early pregnancy. Findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent.


Rebif is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Please see Rebif® Prescribing Information  and Medication Guide.